trial

A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia

NCTId NCT00316238
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 160 (estimated)
Sponsored by Eli Lilly and Company
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
160 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2006-04
Primary completion
—
Eligibility
ALL · 20 Years · 65 Years

Interventions & indications

Drugs
Olanzapine

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

15 total
Akita, JapanFukuoka, JapanFukushima, JapanGunma, JapanHiroshima, JapanHokkaido, JapanKagoshima, JapanKumamoto, JapanNagano, JapanOkayama, JapanOkinawa, JapanOsaka, Japan

Facts & assertions

3 sourced
Enrollment
160
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person